Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 5
1999 5
2001 2
2002 2
2003 3
2004 5
2005 5
2006 4
2007 7
2008 6
2009 6
2010 6
2011 3
2012 3
2013 2
2014 4
2015 3
2016 3
2017 4
2018 2
2019 2
2020 1
2021 1
2023 1
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.
Ofili EO, Cable G, Neutel JM, Saunders E. Ofili EO, et al. J Womens Health (Larchmt). 2008 Jul-Aug;17(6):931-8. doi: 10.1089/jwh.2008.0499. J Womens Health (Larchmt). 2008. PMID: 18681815 Free PMC article. Clinical Trial.
OBJECTIVE: This post hoc analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of irbesartan/hydrochlorothiazide (HCTZ) in a diverse population of hyp …
OBJECTIVE: This post hoc analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populatio …
Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.
Hedaya MA, Helmy SA. Hedaya MA, et al. Biopharm Drug Dispos. 2015 May;36(4):216-31. doi: 10.1002/bdd.1935. Epub 2015 Feb 4. Biopharm Drug Dispos. 2015. PMID: 25545238 Clinical Trial.
The PK parameters of irbesartan were not affected by hydrochlorothiazide; however irbesartan decreased the hydrochlorothiazide AUC by 25% and increased its clearance by 25%. There were no significant changes in heart rate after each drug alone or in co …
The PK parameters of irbesartan were not affected by hydrochlorothiazide; however irbesartan decreased the hydrochlo …
Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension.
Yan P, Luo Y, Zhang J, Liu H, Chen J, Wang J, Dong G, Ge M. Yan P, et al. J Clin Hypertens (Greenwich). 2023 Feb;25(2):137-145. doi: 10.1111/jch.14630. Epub 2023 Jan 14. J Clin Hypertens (Greenwich). 2023. PMID: 36639984 Free PMC article. Clinical Trial.
This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) …
This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at diff …
Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
Chrysant SG, Neutel JM, Ferdinand KC; INCLUSIVE investigators. Chrysant SG, et al. J Natl Med Assoc. 2009 Apr;101(4):300-7. doi: 10.1016/s0027-9684(15)30876-2. J Natl Med Assoc. 2009. PMID: 19397219 Clinical Trial.
This post hoc analysis of the Irbesartan/Hydrochlorothiazide (HCTZ) Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) trial evaluated the efficacy and safety of fixed-dose irbesartan/HCTZ in patients with isolated systolic hypertension. ... …
This post hoc analysis of the Irbesartan/Hydrochlorothiazide (HCTZ) Blood Pressure Reductions in Diverse Patient Populations ( …
Alcohol Consumption and Antihypertensive Treatment Effect in Male Patients With Hypertension.
Ye XF, Wang WY, Wang XY, Huang QF, Li Y, Wang JG. Ye XF, et al. Am J Hypertens. 2024 Jan 16;37(2):112-119. doi: 10.1093/ajh/hpad091. Am J Hypertens. 2024. PMID: 37769181 Free article. Clinical Trial.
METHODS: The study participants were patients enrolled in a 12-week therapeutic study and treated with the irbesartan/hydrochlorothiazide combination 150/12.5 mg once daily, with the possible up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks of foll …
METHODS: The study participants were patients enrolled in a 12-week therapeutic study and treated with the irbesartan/hydrochlorot …
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, Vo K, Rogers K, Atkins E, Webster R, Chou M, Dehbi HM, Salam A, Patel A, Neal B, Peiris D, Krum H, Chalmers J, Nelson M, Reid CM, Woodward M, Hilmer S, Thom S, Rodgers A. Chow CK, et al. Lancet. 2017 Mar 11;389(10073):1035-1042. doi: 10.1016/S0140-6736(17)30260-X. Epub 2017 Feb 10. Lancet. 2017. PMID: 28190578 Free article. Clinical Trial.
METHODS: We did a randomised, placebo-controlled, double-blind, crossover trial of a quadpill-a single capsule containing four blood pressure-lowering drugs each at quarter-dose (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiazide 6.25 mg, and atenolol 12.5 …
METHODS: We did a randomised, placebo-controlled, double-blind, crossover trial of a quadpill-a single capsule containing four blood pressur …
The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.
Raskin P, Guthrie R, Flack J, Reeves R, Saini R. Raskin P, et al. J Hum Hypertens. 1999 Oct;13(10):683-7. doi: 10.1038/sj.jhh.1000888. J Hum Hypertens. 1999. PMID: 10516738 Clinical Trial.
The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hypertensive patients (seated diastolic blood pressure [SeDBP] 95-110 mm Hg). Patients (n = 1098) completing two randomised, double-blind trial …
The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hyp …
Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD.
Jiang GY, Li Q, Lv YX. Jiang GY, et al. Int J Chron Obstruct Pulmon Dis. 2018 Dec 20;14:73-80. doi: 10.2147/COPD.S186872. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30587963 Free PMC article. Clinical Trial.
In addition to standard treatment for AECOPD, the subjects in group I were treated with irbesartan alone, and those in group II were treated with irbesartan and hydrochlorothiazide for a week. ...There were no significant differences in 36-item short-form dom …
In addition to standard treatment for AECOPD, the subjects in group I were treated with irbesartan alone, and those in group II were …
Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
Lewin AJ, Weir MR. Lewin AJ, et al. Clin Ther. 2008 Dec;30(12):2354-65. doi: 10.1016/j.clinthera.2008.12.018. Clin Ther. 2008. PMID: 19167594 Clinical Trial.
METHODS: The 18-week, prospective, multicenter, open-label, single-arm INCLUSIVE trial evaluated the efficacy and tolerability of a fixed-dose combination of irbesartan/hydrochlorothiazide (HCTZ) in adult hypertensive patients with systolic blood pressure (SBP) that …
METHODS: The 18-week, prospective, multicenter, open-label, single-arm INCLUSIVE trial evaluated the efficacy and tolerability of a fixed-do …
Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.
Liu J, Wu L, Hu X, Wu G, Zheng Y, Zhou H, Zhai Y, Zhu M, ShenTu J. Liu J, et al. Int J Clin Pharmacol Ther. 2015 Jul;53(7):573-81. doi: 10.5414/CP202208. Int J Clin Pharmacol Ther. 2015. PMID: 25828636 Clinical Trial.
OBJECTIVES: The aim of the present study was to compare the pharmacokinetic profiles between a new generic and a branded reference formulation of irbesartan/ hydrochlorothiazide FDC tablets, and to assess the bioequivalence of the two products in healthy Chinese mal …
OBJECTIVES: The aim of the present study was to compare the pharmacokinetic profiles between a new generic and a branded reference formulati …
76 results